S4C2：Biologic Clinical Considerations

原文始发于微信公众号（化学音乐文化）：S4C2：Biologic Clinical Considerations

JanFourman,PhD, EdD,MBA, MSRA

S4C2：Biologic Clinical Considerations

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years

Eli Lilly – Pharmacovigilance – 7 years

Eli Lilly – Regulatory Intelligence – 3 Years

Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US

Consultant for Indiana Technical Assistance Program

Invited conference speaker

Published author

扫描左侧二维码，获取视频课；扫描右侧二维码，获取音频课

Biologics OverviewPart 1 – Introduction

Safety with Biologics Introduction:

Gain a better understanding of biologic agents, risk factors and potential Mechanism of Actions (MOAs) as it relates to safety

Part 2 – Preclinical Considerations

Nonclinical safety evaluation general concepts

Biologics approach

Supporting First Human Dose (FHD)

Species selection

Tissue cross-reactivity

Repeat-dose toxicity

Regulatory filing considerations

Immunogenicity and immunotoxicity assessments

Developmental and reproductive toxicity testing

Carcinogenicity assessment

发布者：药时代，转载请首先联系contact@drugtimes.cn获得授权